TY  - JOUR
AU  - Van Cutsem, Eric
AU  - Mayer, Robert J
AU  - Laurent, Stéphanie
AU  - Winkler, Robert
AU  - Grávalos, Cristina
AU  - Benavides, Manuel
AU  - Longo-Munoz, Federico
AU  - Portales, Fabienne
AU  - Ciardiello, Fortunato
AU  - Siena, Salvatore
AU  - Yamaguchi, Kensei
AU  - Muro, Kei
AU  - Denda, Tadamichi
AU  - Tsuji, Yasushi
AU  - Makris, Lukas
AU  - Loehrer, Patrick
AU  - Lenz, Heinz-Josef
AU  - Ohtsu, Atsushi
AU  - RECOURSE Study Group
PY  - 2017
DO  - 10.1016/j.ejca.2017.10.009
UR  - http://hdl.handle.net/10668/11947
T2  - European journal of cancer (Oxford, England : 1990)
AB  - In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard...
LA  - en
KW  - Fluoropyrimidine
KW  - Metastatic colorectal cancer
KW  - Randomised controlled trial
KW  - TAS-102
KW  - Tipiracil
KW  - Trifluridine
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Colorectal Neoplasms
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Drug Combinations
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Pyrrolidines
KW  - Thymine
KW  - Treatment Outcome
KW  - Trifluridine
KW  - Uracil
TI  - The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
TY  - research article
VL  - 90
ER  -